Utility of Routine Hematological Parameters in Monitoring Multiple Myeloma Before and After Autologous Peripheral Blood Stem Cell Transplantation: A Narrative Review

Background

Multiple myeloma (MM) is a clonal plasma-cell malignancy, and its diagnosis and monitoring rely mainly on disease specific investigations. Routine hematological tests remain widely available and are frequently performed before and after autologous peripheral blood stem cell transplantation (aPBSCT), particularly in resource-constrained settings.